Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.
Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.
Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.
Telormedix appoints new chairman
Nicholas Rogerson has taken the role
You may also like
Sustainability
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Regulatory
The key role of IVDs in healthcare: challenges to commercialisation and access
In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment